| Primary |
| Drug Use For Unknown Indication |
34.0% |
| Hypertension |
16.0% |
| Atrial Fibrillation |
14.0% |
| Acute Myocardial Infarction |
8.0% |
| Cardiac Failure Congestive |
8.0% |
| Cardiomyopathy |
6.0% |
| Hyperthyroidism |
4.0% |
| Myocardial Ischaemia |
4.0% |
| Essential Hypertension |
2.0% |
| Hyperuricaemia |
2.0% |
| Neoplasm Malignant |
2.0% |
|
| Renal Failure Acute |
15.4% |
| Drug Interaction |
11.5% |
| Syncope |
11.5% |
| Rash Papulosquamous |
7.7% |
| Atrial Fibrillation |
3.8% |
| Atrioventricular Block |
3.8% |
| Bradyarrhythmia |
3.8% |
| Cerebral Haemorrhage |
3.8% |
| Dyspnoea |
3.8% |
| Loss Of Consciousness |
3.8% |
| Pleural Effusion |
3.8% |
| Productive Cough |
3.8% |
| Renal Failure |
3.8% |
| Respiratory Tract Infection |
3.8% |
| Speech Disorder |
3.8% |
| Therapeutic Agent Toxicity |
3.8% |
| Vitreous Floaters |
3.8% |
| Vomiting |
3.8% |
|
| Secondary |
| Drug Use For Unknown Indication |
31.7% |
| Hypertension |
12.2% |
| Acute Myocardial Infarction |
9.8% |
| Diabetes Mellitus |
9.8% |
| Product Used For Unknown Indication |
9.8% |
| Cardiac Failure Congestive |
7.3% |
| Emphysema |
4.9% |
| Prophylaxis |
4.9% |
| Anaemia |
2.4% |
| Arrhythmia |
2.4% |
| Atrial Fibrillation |
2.4% |
| Cardiac Disorder |
2.4% |
|
| Diabetes Mellitus |
33.3% |
| Angioedema |
13.3% |
| Dyspnoea |
13.3% |
| Renal Failure Acute |
13.3% |
| Diarrhoea |
6.7% |
| Hepatitis Acute |
6.7% |
| Pleural Effusion |
6.7% |
| Speech Disorder |
6.7% |
|
| Concomitant |
| Hypertension |
25.7% |
| Cardiac Failure |
12.6% |
| Drug Use For Unknown Indication |
8.3% |
| Atrial Fibrillation |
5.0% |
| Diabetes Mellitus |
4.8% |
| Pain |
4.8% |
| Colorectal Cancer |
4.3% |
| Acute Myocardial Infarction |
3.8% |
| Product Used For Unknown Indication |
3.5% |
| Prophylaxis |
3.5% |
| Osteoporosis |
3.0% |
| Type 2 Diabetes Mellitus |
3.0% |
| Breast Cancer |
2.8% |
| Myocardial Ischaemia |
2.5% |
| Cardiac Failure Congestive |
2.3% |
| Hypercholesterolaemia |
2.3% |
| Ischaemic Cardiomyopathy |
2.3% |
| Arrhythmia |
2.0% |
| Cardiovascular Event Prophylaxis |
1.8% |
| Chronic Obstructive Pulmonary Disease |
1.8% |
|
| Renal Failure Acute |
15.8% |
| Hyperkalaemia |
14.5% |
| Drug Interaction |
7.9% |
| Rhabdomyolysis |
7.9% |
| Renal Failure |
6.6% |
| Vomiting |
6.6% |
| Amaurosis Fugax |
3.9% |
| Hyponatraemia |
3.9% |
| Pyelonephritis |
3.9% |
| Adenocarcinoma Pancreas |
2.6% |
| Atrioventricular Block Second Degree |
2.6% |
| Disorientation |
2.6% |
| Drug Ineffective |
2.6% |
| Dyspnoea |
2.6% |
| Gait Disturbance |
2.6% |
| Hypoglycaemia |
2.6% |
| Myocardial Infarction |
2.6% |
| Pain |
2.6% |
| Respiratory Distress |
2.6% |
| Sepsis |
2.6% |
|
| Interacting |
| Hypertension |
50.0% |
| Atrial Fibrillation |
21.7% |
| Cardiac Failure |
6.7% |
| Gout |
6.7% |
| Prophylaxis |
5.0% |
| Anaemia |
1.7% |
| Cardiovascular Event Prophylaxis |
1.7% |
| Hyperuricaemia |
1.7% |
| Liver Transplant |
1.7% |
| Product Used For Unknown Indication |
1.7% |
| Renal Failure Chronic |
1.7% |
|
| Renal Failure Acute |
35.3% |
| Vomiting |
23.5% |
| Shock |
11.8% |
| Drug Interaction |
5.9% |
| Loss Of Consciousness |
5.9% |
| No Adverse Event |
5.9% |
| Oxygen Saturation Decreased |
5.9% |
| Urinary Tract Infection |
5.9% |
|
